Butafosfan: diferentes formas farmacêuticas para uso em animais de produção

Abstract

The recent postpartum of dairy cows is a period characterized by a decrease in dry matter intake and, consequently, a more intense negative energy balance. In order to mitigate this balance, several strategies are being used, such as organic phosphorus-based energy supplements, such as Butafosfan. The objective of this study was to evaluate different pharmaceutical forms of Butafosfan on metabolic and zootechnical parameters in postpartum dairy cows. A total of 37 Holstein cows, multiparous, from a farm in the south of Rio Grande do Sul. The animals were randomly divided into three groups to receive three subcutaneous doses in the cervical region, according to the prediction of delivery, certain pharmaceutical form. Group BUT (n = 12) received 90mL Butafosfan solution (13.5g); BUTSR (n = 12) received 90mL of sustained release formulation of Butafosfan (13.5g) and Group CL (Control; n = 12) received 90mL of water for injectables. The applications occurred on the day of parturition (day 0, within 12 hours postpartum) and on days 3 and 7 postpartum. Blood samples were collected on days 0, 3, 7 and 10 postpartum, by puncture of the coccygeal vein, for the analysis of phosphorus, calcium, magnesium, glucose, total proteins, albumin, urea, globulins, paraoxanase-1, beta-hydroxybutyrate, aspartate aminotransferase and gamma glutamyltransferase. On day 0 and 10 postpartum the body condition score and weight were measured, in addition to daily milk production (from day 11 to 60 days postpartum). Milk production was higher in the BUTSR and BUT groups, when compared to the CL group, but when compared to each other, the BUTSR group presented higher production than the BUT group. The BUTSR and BUT treatments increased calcium levels and decreased glucose concentration, compared to the CL group. The animals in the BUTSR group had increased albumin and urea levels compared to the CL group, which did not differ from the BUT treatment. Through this study, it was noted that Butafosfan, independent of the pharmaceutical form, may increase the calcium levels of the animals, as well as increase milk production and lower blood glucose levels, presumably by increasing its use compared to the animals in the group control. However, the animals treated with the new platform of sustained release presented higher milk production than the other groups, probably because it allows a slower and prolonged supplementation. However, studies using a larger number of animals and with different doses and days of application are necessary to develop the protocol with the lowest possible number of applications and satisfactory results.